Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD25 monoclonal antibody versus methotrexate for prevention of acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation
ChiCTR2600133108Phase 3Not yet recruiting
- Sponsor
- Union Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daclizumab and methotrexate in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Union Hospital. Primary endpoint: 1-year graft-versus-host disease-free, relapse-free survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
daclizumabmethotrexate
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2600133108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133108.